Retinal and Cognitive Dysfunction in Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

510 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-16

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The retina shares similar embryologic origin, anatomical features and physiological properties with the brain and hence offers a unique and accessible "window" to study the correlates and consequences of subclinical pathology in patients with cognitive impairment. Our hypothesis is that the neurodegeneration of the retina will run in parallel to the neurodegeneration of the brain and, therefore, the signs of neurodysfunction in the retinal assessment will be more evident in those patients with rapid cognitive decline. Microangiopathy will also participate in cognitive decline and its specific role, as well as usefulness of retinal imaging, will be also examined.

This is a multinational and multicentre cross-sectional study and prospective, longitudinal cohort observational study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diabetic Retinopathy as a Marker of Cognitive Dysfunction and Depression

NCT04610749

Diabetic Retinopathy Depression Cognitive Impairment +1 more

COMPLETED

Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy

NCT03490318

Proliferative Diabetic Retinopathy Diabetic Macular Edema

COMPLETED

Brain Connectivity in Age-Related Macular Degeneration

NCT01996215

Age-Related Macular Degeneration

COMPLETED

Neuroretinal Biomarkers in Neurodegenerative Diseases

NCT02047760

Multiple Sclerosis

COMPLETED

Diabetic Retinopathy and Subclinical Signs of Disease Transition

NCT03635671

Diabetic Retinopathy

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consists of two main parts: a cross-sectional part and a longitudinal part, aimed at a) to determine whether functional and/or structural retinal biomarkers or circulating biomarkers are able to differentiate people with mild cognitive impairment (MCI) within the type 2 diabetes (T2D) population (the investigators will be able to do in the cross-sectional study, and, thus, use retina and/or blood biomarkers as a potential proxy to events taking place in the brain); b)to determine whether functional and/or structural retinal biomarkers or circulating biomarkers can be used to determine the speed of cognitive decline in people with T2D and MCI and those at higher risk of developing dementia.

The cross-sectional study will allow characterization of a large group of individuals with T2D (720 participants) and establish correlations between the various functional and structural retinal endpoints obtained and the presence/absence of mild cognitive impairment (MCI) and dementia. The cross-sectional study will allow identification of T2D patients with MCI; of these a group of 168 T2D patients with MCI and a group of T2D patients without MCI (n=63), which will act as a control group, will be then followed prospectively in the longitudinal cohort study to evaluate end points predictive of cognitive decline and dementia.

The primary objective is: to assess whether retinal sensitivity measured by microperimetry is able to predict cognitive decline and progression to dementia in MCI T2D patients.

The secondary objectives are:

1. To assess whether retinal sensitivity, measured by microperimetry, can identify individuals with MCI among people with T2D.
2. To assess whether eye fixation, measured by microperimetry, can identify individuals with MCI among people with T2D.
3. To assess whether eye fixation measured by microperimetry is able to predict rapid cognitive decline in T2D patients with MCI.
4. To define a T2D phenotype at high risk of developing dementia based on retinal imaging and functional retinal assessments.
5. To determine whether retinal imaging and functional retinal assessments may identify individuals with MCI among people with T2D.
6. To define a T2D phenotype at high risk to develop cognitive decline and dementia based on retinal imaging plus brain imaging.
7. To define a T2D phenotype at high risk to develop dementia based on retinal imaging plus brain imaging plus circulating biomarkers.
8. To establish a score to predict cognitive decline or progression from MCI to dementia based on the variables included in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Function Cognitive Dysfunction Microperimetry

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cross-sectional cohort

Up to 720 type 2 diabetic patients (\>5 years duration), older than 65 years of age are expected to be recruited in orfer to asure the sample of 168 patients with MCI and 63 normocognitive fulfilling criteria for the prospective study.

No interventions assigned to this group

Prospective study-MCI

Target 168 Patients from the cross-sectional cohort diagnosed with mild cognitive impairment during the cross-sectional evaluation

No interventions assigned to this group

Prospective study normocognitive

63 Patients from the cross-sectional cohort without mild cognitive impairment evaluated during the cross-sectional evaluation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Type 2 diabetes
2. 65 years and older
3. Diabetes duration of at least 5 years
4. No overt retinopathy on fundus examination or fundus images, as determined by the evaluating ophthalmologist, in one or both eyes, and people with mild to moderate non-proliferative diabetic retinopathy (NPDR) as determined by the evaluating phthalmologists using fundus examination by slit-lamp biomicroscopy.
5. Able to provide informed consent

Prospective study:

In addition to the above, participants enrolled in the prospective longitudinal cohort study should fulfilled the following criteria:

1. Diagnosis of MCI confirmed by a neuropsychological test battery (NTB) and a specialized physician. For the control group the absence of MCI will also be confirmed by a neuropsychological test battery (NTB) and a specialized physician.
2. Diagnosis of no overt or mild to moderate NPDR (ETDRS DR level 20 to 47) confirmed by the reading centre.

Exclusion Criteria

1. Previous history of stroke or neurodegenerative diseases.
2. Severe NPDR, Proliferative DR (PDR), Diabetic Macular Edema (DME) or other eye disorders affecting vision besides these complications of diabetic retinopathy (DR).
3. Previous laser photocoagulation.
4. Other diseases which may induce retinal neurodegeneration (e.g. glaucoma).
5. Subjects with a refractive error ≥ ± 6 D.
6. Media opacities that preclude retinal imaging.
7. HbA1C \> 10% (86 mmol/mol).
8. Severe systemic illness or personal circumstances that would not make it possible for patients to fulfil study protocols.

Prospective study:

In addition to the above, participants enrolled in the prospective longitudinal cohort study should fulfilled the following criteria:

1\. Established dementia.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No